Examples of using Immunogenicity in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Immunogenicity data.
Additional immunogenicity data.
Immunogenicity results with Focetria H1N1v Study V111_03.
No variation in immunogenicity of plasma proteins.
As with all therapeutic proteins, there is a potential for immunogenicity.
For optimal immunogenicity, two doses should be given, 4 weeks apart.
The MAH developed an upgraded manufacturing process to increase immunogenicity.
You want to optimize immunogenicity directly in humans in a Phase I setting?
HOS Final ProtocolAvailable Patient Enrolment Analysis of Data Immunogenicity Sub-study.
Additional Prevenar(7-valent) immunogenicity data: children with sickle cell disease.
Immunogenicity in adolescents aged 11-17 years and adults aged≥ 18 years.
This leads to greatly improved activity, reduced immunogenicity, and a longer half-life time in the body.
Immunogenicity and safety of Silgard have been demonstrated in 9- to 15-year-old boys.
From the quality point of view, there are no technical,analytical or animal tools able to predict immunogenicity of recombinant hepatitis B components in man.
Immunogenicity to abatacept following long-term subcutaneous administration was assessed by a new ECL assay.
The applicant has committed to perform a post-marketing study, in which immunogenicity of Xeomin is further investigated after repeated administration up to 6 injection sessions.
Immunogenicity data are highly dependent on the sensitivity and specificity of the ADA assay.
In the majority of patients, immunogenicity occurred early in treatment and was transient resolving by 2 to 4 months.
Immunogenicity in adults aged 18 to 59 years(N=961) and in subjects aged 60 years and older N=391.
Promising first-time immunogenicity data with a mRNA therapeutic from a Phase IIa study in Prostate cancer.
Immunogenicity data are available in individuals with complement deficiencies, asplenia, or splenic dysfunctions see section 5.1.
In study 008, immunogenicity at month 7 was similar to the response observed in study 001.
High immunogenicity in 16- through 26-year-old MSM was also observed, although lower than in HM, similarly to qHPV vaccine.
Because immunogenicity analyses are product-specific, comparison of antibody rates with those from other products is not appropriate.
Long-term immunogenicity data following the use of Menitorix as a primary and booster vaccination are not yet available see section 5.1.
Immunogenicity was related to age and Month 7 anti-HPV levels were significantly higher in younger individuals below 12 years of age than in those above that age.
Immunogenicity data for subcutaneous use of Epoetin alfa HEXAL in patients at risk for antibody-induced PRCA, i. e. patients with renal anaemia, are not sufficient.
Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal.
Because of TACAs' low immunogenicity, the generation of antibodies against them is a challenging task and requires innovative tools as well as extensive knowledge of the employed technology.